The company's improving adjusted EBITDA trajectory and narrowing guidance suggest a path toward breakeven in H2 2027. Monitor the Guardant Health litigation outcome in the U.K. and any drawdown of the remaining $25M Perceptive credit facility, which would add leverage but also fund growth.
Price Chart
Executive Summary
SOPHiA GENETICS reported Q3 2026 revenue of $24.3M, up 25% YoY, and a net loss of $20.3M, roughly flat YoY. The company guided full-year 2026 revenue to the upper end of its $94M-$96M range and narrowed adjusted EBITDA loss guidance to $29M-$32M, improving from $41.5M in FY 2025. Key operating metrics strengthened: platform analysis volume grew 19% YoY, net dollar retention improved to 118% from 108%, and core genomics customers reached 551.
Key Financial Metrics
Key Facts
- Q3 2026 revenue $24.3M, up 25% YoY from $19.5M
- Net loss $20.3M vs $20.0M in Q3 2025, essentially flat
- SOPHiA DDM Platform revenue $23.8M, up 27% YoY
- Platform analysis volume 117,639, up 19% YoY
- Net dollar retention 118% vs 108% a year ago
- Core genomics customers 551 vs 488 a year ago
- Adjusted EBITDA loss improved 31% YoY to $6.1M
- Full-year 2026 revenue guidance narrowed to upper end of $94M-$96M
- Adjusted EBITDA loss guidance $29M-$32M vs $41.5M in FY 2025
- Cash and cash equivalents $93.7M as of Sep 30, 2026
- Guardant Health litigation ongoing; UPC Court of Appeal confirmed no provisional injunction in July 2026
- Signed 30 new core genomics customers in Q3 2026
Financial Impact
Revenue growth of 25% YoY to $24.3M; net loss unchanged at ~$20M; adjusted EBITDA loss improved 31% to $6.1M
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| SOPHiA DDM Platform | $23.8M | +27.2% |
| Workflow equipment and services | $517.0K | -35.0% |
Risk Factors
- Guardant Health patent litigation in the U.K. and EU remains pending; adverse ruling could block MSK-ACCESS commercialization
- Foreign exchange headwinds noted as a potential drag on Q4 2026 revenue
- Company still loss-making with operating cash burn of $32.3M in 9M 2026
- Potential loss of emerging growth company status by Dec 31, 2026, increasing compliance costs
- High share-based compensation ($12.4M in 9M 2026) and social charges ($5.1M) weigh on reported results
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001840706-26-000350 |
| Document: sophiageneticssaex992q32026.htm | 0001840706-26-000350 |
| Document: sophiageneticssaex993q32026.htm | 0001840706-26-000350 |
| Document: q32026sophiageneticssa6-k.htm | 0001840706-26-000350 |
| Document: 0001840706-26-000350-index-headers.html | 0001840706-26-000350 |
| Document: 0001840706-26-000350-index.html | 0001840706-26-000350 |
| Document: 0001840706-26-000350.txt | 0001840706-26-000350 |
| Earnings Context (Synthetic; results releases only) | 0001840706-26-000350 |
Track record
47 reports on SOPH
5 of 10 bullish or bearish reports moved the stock their way by T+5. Best: +64.11% at T+60 after the Jun 4, 2026 report. 8 of 11 went positive at some point.
Filters
- Nov 17, 2026today Insider Cluster Neutral 3/10 Entry $7.45 Now $7.45 −0.00% settles Nov 25
- Nov 16, 2026today 144 Neutral 2/10 Entry $7.44 Now $7.45 +0.13% settles Nov 24
- Nov 12, 20265d ago Insider Cluster Mixed 4/10 Entry $8.21 Now $7.45 −9.26% settles Nov 20
- Nov 12, 20265d ago SC 13D/A Neutral 3/10 Entry $7.86 Now $7.45 −5.22% settles Nov 19
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $7.86 Now $7.45 −5.22% due Nov 17
- Nov 9, 20268d ago Insider Cluster Bullish 4/10 Entry $7.86 Now $7.45 −5.22% due Nov 17
- Nov 3, 202614d ago 6-K Neutral 5/10 Viewing No price data
- Nov 3, 202614d ago Press Release Neutral 5/10 Entry $6.91 to $7.86 Now $7.45 +7.81% ▲ +13.75% +14.34% vs SPY
- Oct 14, 20264w ago Insider Cluster Neutral 2/10 Entry $7.29 to $7.05 Now $7.45 +2.19% ▼ −3.29% −2.28% vs SPY
- Oct 5, 20266w ago 144 Neutral 2/10 Entry $7.38 to $7.09 Now $7.45 +0.95% ▼ −3.93% −3.79% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers